🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. Olezarsen

    IONIS PHARMACEUTICALS INC

    Severe Hypertriglyceridemia

    phase 3 small molecule completed

    3 trials

  2. Olezarsen

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 3 small molecule active

    3 trials

  3. Olorofim

    Biotech Pharmaceutical Co.,

    Invasive Aspergillosis

    phase 3 small molecule active

    1 trial

  4. Olumiant 4 mg film-coated tablets, Placebo of Olumiant 4mg

    Pari Pharma GmbH

    Dermatomyositis; Baricitinib in patients with relapsing or naïve dermatomyositis.

    phase 3 small molecule active

    1 trial

  5. Olverembatinib

    Ascentage Pharma Group

    Ph+ ALL

    phase 3 small molecule active

    1 trial

  6. Once weekly subcutaneous injection of TransCon hGH

    Ascendis Pharma Endocrinology Division A/S

    Growth Hormone Deficiency, Pediatric

    phase 3 small molecule completed

    1 trial

  7. Opaganib

    RedHill Biopharma

    COVID-19

    phase 3 small molecule terminated

    2 trials

  8. OraVescent Fentanyl

    Teva Pharma GmbH

    Low Back Pain

    phase 3 small molecule completed

    1 trial

  9. OraVescent Fentanyl

    Teva Pharma GmbH

    Pain

    phase 3 small molecule completed

    1 trial

  10. OraVescent fentanyl (OVF)

    Teva Pharma GmbH

    Pain

    phase 3 small molecule completed

    1 trial

  11. OraVescent fentanyl citrate

    Teva Pharma GmbH

    Pain

    phase 3 small molecule completed

    1 trial

  12. Orelabrutinib

    Zenas BioPharma

    Multiple Sclerosis (MS) Primary Progressive

    phase 3 small molecule active

    1 trial

  13. Orelabrutinib

    Zenas BioPharma

    Secondary Progressive Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  14. Orelabrutinib, Placebo tablets match with that of orelabrutinib (ICP-022) tablets in appearance, shape, size, and weight.

    Zenas BioPharma

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  15. Orodispersible tablet, BUL03, Jorveza 1 mg orodispersible tablets

    Dr. Falk Pharma GmbH

    eosinophilic esophagitis

    phase 3 small molecule active

    1 trial

  16. Oxcarbazepine XR

    SUPERNUS PHARMACEUTICALS, INC.

    Partial Epilepsy

    phase 3 small molecule completed

    1 trial

  17. Oxybutinyn Vaginal Ring 4mg

    Teva Pharma GmbH

    Overactive Bladder

    phase 3 small molecule completed

    1 trial

  18. Oxycodone DETERx

    COLLEGIUM PHARMACEUTICAL, INC

    Chronic Low Back Pain

    phase 3 small molecule completed

    1 trial

  19. Oxycodone Naltrexone (a)

    ELITE PHARMACEUTICALS INC /NV/

    Pain

    phase 3 small molecule completed

    1 trial

  20. Oxycodone/Naltrexone Capsules

    ELITE PHARMACEUTICALS INC /NV/

    Withdrawal Symptoms

    phase 3 small molecule completed

    1 trial

  21. Oxymetazoline Hydrochloride

    Teva Pharma GmbH

    Rosacea

    phase 3 small molecule completed

    1 trial

  22. P1101

    PharmaEssentia

    Polycythemia Vera (PV)

    phase 3 small molecule completed

    1 trial

  23. PACLITAXEL, ALPELISIB, DOXORUBICIN HYDROCHLORIDE, OLAPARIB, ALPELISIB, OLAPARIB

    Novartis Pharmaceuticals

    Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation

    phase 3 small molecule active

    1 trial

  24. PARACETAMOL , Dapirolizumab pegol, Placebo matching dapirolizumab pegol and without active substance, -, DIPHENHYDRAMINE , -, EPINEPHRINE , -, -

    Lacuna Pharma Pty Ltd

    Systemic lupus erythematosus (SLE)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources